Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Feb 15, 2020; 12(2): 124-148
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.124
Published online Feb 15, 2020. doi: 10.4251/wjgo.v12.i2.124
Study setting | Sample type | Marker type | Biomarker(s) | Sensitivity (or its range) | Specificity (or its range) | Ref. |
Screening (reviewed) | Stool | Protein | Haemoglobin (FIT) | 66.0%-74.0% | 84.0%-95.0% | [31] |
Case-control (reviewed) | Stool | Protein | M2-PK | 68.0%-93.0% | 70.0%-97.5% | [32,33] |
Case-control | Stool | Protein | MMP 9 | 89.30% | 91.20% | [34] |
Case-control | Stool | Protein panel | Complement C3, Lactotransferrin, Haemoglobin subunit α1 and Haptoglobin | 71.00% | 95.00% | [35] |
Case-control | Serum | Protein | CA11-19 | 98.00% | 84.00% | [36] |
Case-control | Serum | Protein (cytokine) | MIC-1 (GDF15) | 43.80% | 96.70% | [36] |
Case-control | Serum | Protein (cytokine) | IL-6 | 28.0%-89.5% | 46.0%-94.0% | [37] |
Case-control | Serum | Protein (cytokine) | IL-8 | 70.00% | 91.00% | [36] |
Case-control | Serum | Protein (cytokine) | Growth-related gene product β1 | 56.10% | 95.30% | [36] |
Case-control | Serum | Protein | Cyr61 | 83.00% | 97.00% | [38] |
Case-control | Serum | Protein | Β6-integrin | 69.80% | 100.00% | [39] |
Case-control (reviewed) | Serum | Protein | TIMP-1 | 52.0%-85.0% | 60.0%-95.0% | [40] |
Case-control | Serum | Protein | RBP4 | 74.90% | 81.70% | [36] |
Case-control | Serum | Protein | THBS2 | 64.90% | 87.10% | [36] |
Case-control | Serum | Protein | TFF3 | 74.20% | 94.80% | [36] |
Case-control | Serum | Protein | COL3A1 | 98.80% | 69.10% | [36] |
Case-control | Serum | Protein | COL10A1 | 63.00% | 85.00% | [36] |
Case-control | Serum | Protein | AZGP1 | 55.80% | 85.00% | [36] |
Case-control | Serum | Protein | Angiopoietin-2 | 79.30% | 82.40% | [36] |
Case-control | Serum | Protein | Kininogen | 63.60% | 65.90% | [36] |
Case-control | Plasma | Protein | Melanotransferrin | 48.20% | 92.50% | [36] |
Case-control | Serum | Protein panel | RBP4 and CEA | 80.80% | 91.20% | [36] |
Case-control | Serum | Protein panel | TFF3 and CEA | 89.40% | 87.80% | [41] |
Case-control | Serum | Protein panel | sDC-SIGN and sDC-SIGNR | 98.70% | 94.80% | [42] |
Case-control | Serum | Protein panel | IGFBP-3 and CEA | 75.00% | 90.00% | [43] |
Case-control | Serum | Protein panel | AZGP1, CEA and CA19-9 | 67.50% | 82.50% | [36] |
Case-control | Serum | Protein panel | IGFBP2, DKK3 and PKM2 | 73.00% | 95.00% | [36] |
Case-control | Plasma | Protein panel | BAG4, IL6ST, VWF, EGFR and CD44 | 73.00% | 90.00% | [44] |
Case-control, prospective | Serum | Protein panel | CEA, hs-CRP, CYFra21-1 and Ferritin | 60.0%-70.0% | 81.0%-89.0% | [45] |
- Citation: Loktionov A. Biomarkers for detecting colorectal cancer non-invasively: DNA, RNA or proteins? World J Gastrointest Oncol 2020; 12(2): 124-148
- URL: https://www.wjgnet.com/1948-5204/full/v12/i2/124.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i2.124